Skip to content
Politically.com Search all
Menu

2025 · 4th Quarter (Oct 1 - Dec 31)

MERCK & CO INC

Filed by MERCK & CO, INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
4th Quarter - Report
Posted
Jan 20, 2026
Income
Not reported
Expenses
$1,930,000.00
Filing UUID
816a1203-c5d8-45b8-97e8-2c50a12596b5
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing.

Literal federal measure citations: S. 1339, S. 2076

MMM · Medicare/Medicaid

Issues relating to, One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Medicaid drug rebate program Cost and value of medicines: Drug pricing and reimbursement issues; FY-2026 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP).

TAX · Taxation/Internal Revenue Code

Issues relating to, Tax reform and tax policy, generally; Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes.

ANI · Animals

Issues relating to, Agriculture; Animal Health Technology; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Rural development; Administration and related agencies appropriations bill, FY-26.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.